CRYOPORT, INC. Revenue from Contract with Customer, Excluding Assessed Tax
CRYOPORT, INC. (CYRX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $48.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- CRYOPORT, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $48.97M, a 7.74% increase year-over-year.
- CRYOPORT, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $47.80M, a 16.47% increase year-over-year.
- CRYOPORT, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $45.45M, a 9.64% increase year-over-year.
- CRYOPORT, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $44.23M, a 15.44% increase year-over-year.
- CRYOPORT, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $176.18M, a 12.38% increase from fiscal 2024.
- CRYOPORT, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $156.77M, a 7.05% decline from fiscal 2023.
- CRYOPORT, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $168.66M, a 28.92% decline from fiscal 2022.
- CRYOPORT, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $237.28M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $48.97M 10-Q · filed 2026-08-06 | $96.77M 10-Q · filed 2026-08-06 | $142.22M derived: sum of 3 quarters · filed 2026-08-06 | $186.45M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $47.80M 10-Q · filed 2026-05-05 | $93.25M derived: sum of 2 quarters · filed 2026-05-05 | $137.48M derived: sum of 3 quarters · filed 2026-05-05 | $182.94M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $45.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $89.68M derived: sum of 2 quarters · filed 2026-03-05 | $135.14M derived: sum of 3 quarters · filed 2026-08-06 | $176.18M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $44.23M 10-Q · filed 2025-11-06 | $89.69M derived: sum of 2 quarters · filed 2026-08-06 | $130.73M 10-Q · filed 2025-11-06 | $172.18M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $45.45M 10-Q · filed 2026-08-06 | $86.49M 10-Q · filed 2026-08-06 | $127.95M derived: sum of 3 quarters · filed 2026-08-06 | $166.26M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $41.04M 10-Q · filed 2026-05-05 | $82.49M derived: sum of 2 quarters · filed 2026-05-05 | $120.81M derived: sum of 3 quarters · filed 2026-05-05 | $160.52M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $41.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $79.77M derived: sum of 2 quarters · filed 2026-03-05 | $119.48M derived: sum of 3 quarters · filed 2026-03-05 | $156.77M 10-K · filed 2026-03-05 | $228.38M 10-K · filed 2025-03-07 |
| 2024-09-30 | $38.32M 10-Q · filed 2025-11-06 | $78.03M derived: sum of 2 quarters · filed 2025-11-06 | $115.32M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $39.71M 10-Q · filed 2025-08-12 | $77.00M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $37.29M 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | $168.66M 10-K · filed 2026-03-05 | $233.25M 10-K · filed 2025-03-07 | |||
| 2022-12-31 | $237.28M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |